Cognivia Secures Strategic 15.5M€ Funding to Empower Drug Development with AI-ML Solutions
Summary
Vesalius Biocapital IV, SFPIM (Soci\xe9t\xe9 F\xe9d\xe9rale de Participations et dInvestissement) and WE (Wallonie Entreprendre) have committed strategic investments to drive Cognivias mission to "quantify the power of the mind" to optimize and accelerate drug development programs. This strategic maneuver is in perfect alignment with Cognivias steadfast dedication to becoming a leading partner for pharmaceutical and biotechnology companies, empowering them to develop efficacious treatments to address unmet patient needs.In this latest funding round, Cognivia proudly welcomes the support of three esteemed investors: Vesalius Biocapital IV, a Luxembourg-based venture-capital fund focusing on best-in-class investments in HealthTech and biopharma; SFPIM, the Belgian Sovereign Wealth Fund, providing strategic guidance and financial support for Belgian companies; and WE, contributing to Wallonias economic development through financing and support across various sectors. "We are thrilled to announce Cognivia as the inaugural investment of our fund IV, which focuses on HealthTech and biopharma companies at the forefront of innovation transforming healthcare. "With this investment and the welcomed addition of new members to our operational team and Company Board and Strategic Advisory Committee, to be announced soon, we are poised to accelerate our efforts in delivering groundbreaking approaches that empower clinicians, researchers and industries to make informed, data-driven decisions, ultimately enhancing outcomes for patients and stakeholders worldwide. "Cognivia is the first and only company to combine quantification of patient psychology with artificial intelligence (AI)/machine learning (ML) to improve measurement of therapeutic efficacy in clinical trials and beyond.